<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796688</url>
  </required_header>
  <id_info>
    <org_study_id>Universal AT19 cells</org_study_id>
    <nct_id>NCT04796688</nct_id>
  </id_info>
  <brief_title>Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies</brief_title>
  <official_title>Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients With CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu USino Technology Biology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, single-arm study to evaluate the primary safety and&#xD;
      efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed&#xD;
      or refractory hematological malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Adoptive transfer of autologous anti-CD19 CAR-T cells can induce durable remissions in&#xD;
           patients with relapsed/refractory hematologic malignancies, including CD19+ B-cell acute&#xD;
           lymphoblastic leukemia(B-ALL), B-cell chronic lymphoblastic leukemia(B-CLL), and B-cell&#xD;
           lymphoma.&#xD;
&#xD;
        -  However, multiple challenges exist for manufacturing CAR-T cells from patients with&#xD;
           advanced disease including inability to manufacture a product, disease progression or&#xD;
           death while waiting for the CAR-T product to be available, and heterogeneity among&#xD;
           autologous CAR-T products that contributes to unpredictable and variable clinical&#xD;
           activity.&#xD;
&#xD;
        -  Healthy donor T cells can provide a source for production of universal CAR-T cells when&#xD;
           combined with gene editing to prevent expression of endogenous TCRs and avoid generation&#xD;
           of GvHD in HLA mismatched recipients.&#xD;
&#xD;
        -  Cord blood derived T cells from healthy donor are the source for production of universal&#xD;
           anti-CD19 CAR-modified AT19 cells. CRISPR/cas9 gene-editing technology has been used to&#xD;
           knockout TCRs and HLA-I to avoid GvHD and transplant rejection.&#xD;
&#xD;
        -  AT19 cells have exhibited potent cytotoxicity in CD19+ tumor cells and can effectively&#xD;
           eradicate CD19+ tumor cells in xenograft mice models, without showing GvHD.&#xD;
&#xD;
        -  This study aims to evaluate prelimary safety and efficacy of the universal AT19 cells in&#xD;
           patients with relapsed/refractory B-ALL, B-CLL, and B-cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related Adverse Events</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate(ORR) of administering AT19 cells in Relapsed/Refractory CD19+ B-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>ORR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate(CRR) of administering AT19 cells in Relapsed/Refractory CD19+ B-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>CRR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival(PFS) of administering AT19 cells in Relapsed/Refractory CD19+ B-cell hematological malignancies.</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>PFS will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR) of administering AT19 cells in Relapsed/Refractory CD19+ B-cell hematological malignancies.</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>DOR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS) of administering AT19 cells in Relapsed/Refractory CD19+ B-cell hematological malignancies.</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>OS will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>In vivo expansion and survival of AT19 cells</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>Quantity of AT19 CAR copies in bone marrow and peripheral blood will be determined by using qPCR.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Lymphoblastic Leukemia</condition>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + AT19 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10^7, 1.0×10^7, and 2.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells</intervention_name>
    <description>fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + AT19 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 14-78 years old (including 14 and 78 years old).&#xD;
&#xD;
          2. Clinical diagnosis of CD19+ B-cell hematological malignancies, including acute&#xD;
             lymphoblastic leukemia, chronic lymphocytic leukemia and lymphoma.&#xD;
&#xD;
          3. Refractory/Relapsed B-cell malignancies:&#xD;
&#xD;
             A. Refractory/relapsed B-cell lymphoblastic leukemia, meeting one of the following&#xD;
             criteria:&#xD;
&#xD;
             i. Recurrence within 6 months after first remission. ii. Primary refractory disease&#xD;
             which cannot achieve complete remission (CR) after 2 cycles of standardized&#xD;
             chemotherapy regimen.&#xD;
&#xD;
             iii. Failure to achieve CR or relapse after one line or multiple lines of salvage&#xD;
             chemotherapy.&#xD;
&#xD;
             iv. Not suitable for hematopoietic stem cell transplantation (HSCT), or abandon HSCT&#xD;
             due to various restrictions, or relapse after HSCT.&#xD;
&#xD;
             B. Refractory/relapsed B-cell lymphoma, meeting 1 of the first 4 items plus item 5: i.&#xD;
             Tumor shrinkage less than 50% or disease progression after 4 cycles of standard&#xD;
             chemotherapy.&#xD;
&#xD;
             ii. Achieved CR after standard chemotherapy, but relapsed within 6 months. iii. 2 or&#xD;
             more relapses after CR. iv. Not suitable for HSCT, or abandon HSCT due to various&#xD;
             restrictions, or relapse after HSCT.&#xD;
&#xD;
             v. Subjects must have received adequate treatment in the past, including anti-CD20&#xD;
             monoclonal antibody and combination chemotherapy with anthracyclines.&#xD;
&#xD;
          4. Having a measurable or evaluable lesion:&#xD;
&#xD;
             A. Patients with lymphoma require a single lesion≥15mm or 2 or more lesions≥10mm.&#xD;
&#xD;
             B. Patients with leukemia require persistent positive or positive relapse of bone&#xD;
             marrow MRD.&#xD;
&#xD;
          5. The toxicity related to previous treatments had returned to &lt; 1 level at enrollment&#xD;
             (except for low grade toxicity such as alopecia).&#xD;
&#xD;
          6. Patients have good main organs functions:&#xD;
&#xD;
             A. Liver function: ALT/AST &lt; 2.5 times the upper limit of normal (ULN) and total&#xD;
             bilirubin≤ 1.5 times ULN; B. Renal function: Creatinine clearance rate ≥ 60ml/min. C.&#xD;
             Pulmonary function: Indoor oxygen saturation ≥ 95%. D. Cardiac Function: Left&#xD;
             ventricular ejection fraction (LVEF) ≥50%, no clinically-significant ECG findings.&#xD;
&#xD;
          7. Estimated survival time≥3 months.&#xD;
&#xD;
          8. Patient or his or her legal guardian voluntarily participates in and signs an informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system is involved in leukemia and lymphoma.&#xD;
&#xD;
          2. Known HIV positive patients.&#xD;
&#xD;
          3. CNS diseases, such as epilepsy, cerebral ischemia / hemorrhage, dementia, cerebellar&#xD;
             diseases or any CNS related autoimmune diseases.&#xD;
&#xD;
          4. NYHA class III or higher cardiac failure, or with malignant arrhythmia.&#xD;
&#xD;
          5. Myocardial infarction, angioplasty or stent placement, unstable angina or other&#xD;
             clinically significant heart history within 12 months before enrollment.&#xD;
&#xD;
          6. Patients who need immediate treatment to control tumor progression or relieve tumor&#xD;
             burden.&#xD;
&#xD;
          7. Active autoimmune diseases requiring systemic immunosuppressive therapy.&#xD;
&#xD;
          8. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months&#xD;
             before enrollment.&#xD;
&#xD;
          9. Severe immediate hypersensitivity to any drug to be used in this study.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         11. Other unsuitable conditions in the researchers' opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heng Mei, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heng Mei, M.D., Ph.D</last_name>
    <phone>027-8572600</phone>
    <email>hmei@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenggong Li</last_name>
    <phone>18868112136</phone>
    <email>chenggongli@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <email>hmei@hust.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chenggong Li</last_name>
      <email>chenggongli@hust.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <email>hmei@hust.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chenggong Li</last_name>
      <email>chenggongli@hust.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>MEI HENG</investigator_full_name>
    <investigator_title>Proferssor, Cheif Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

